Drug Trial Radar · NCT05186922
The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Mar 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
54
Planned (sponsor's estimate)
Start
Feb 17, 2022
Primary completion
Jan 2023
Study completion Jan 2023
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of CM326 in moderate-severe AD subjects.
Conditions
- Moderate-to-severe Atopic Dermatitis
Interventions
CM326Biological
CM326 injection
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AE)Time frame: Up to week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.